about
Undifferentiated connective tissue disease presenting with prevalent interstitial lung disease: case report and review of literatureHow the Mediterranean diet and some of its components modulate inflammatory pathways in arthritisAutoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's diseaseMud-bath treatment in spondylitis associated with inflammatory bowel disease--a pilot randomised clinical trialWorking the endless puzzle of hereditary autoinflammatory disorders.High-density lipoproteins downregulate CCL2 production in human fibroblast-like synoviocytes stimulated by urate crystals.The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-κB pathwayLaboratory investigations in osteoarthritis.Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis.Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept.A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study.Methods used to assess remission and low disease activity in rheumatoid arthritis.Molecular pathways involved in synovial cell inflammation and tumoral proliferation in diffuse pigmented villonodular synovitis.Miscellaneous non-inflammatory musculoskeletal conditions. Blau syndrome.Blau syndrome, clinical and genetic aspects.The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up.Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis.Systemic vasculitis and pregnancy: a multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies.Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study.IL-1ß and IL-8 are scavenged by the hexadecylamide derivative of hyaluronic acid: a new mechanism.Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients.Impact of 24 months of anti-TNF therapy versus methotrexate on body weight in patients with rheumatoid arthritis: a prospective observational study.Epigallocatechin-3-gallate reduces inflammation induced by calcium pyrophosphate crystals in vitroEx vivo and in vitro production of pro-inflammatory cytokines in Blau syndrome.Clinical Overlapping in Autoinflammatory Diseases: The Role of Gene Duplication.Response to 'Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via Toll-like receptor 4'.Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-α blockade in the knee joint.Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate.The social costs of digital ulcer management in sclerodema patients: an observational Italian pilot study.Clinical manifestations and outcome of polyarthralgia associated with chronic lymphocytic thyroiditis.Serum and salivary neopterin and interferon-gamma in primary Sjögren's syndrome. Correlation with clinical, laboratory and histopathologic features.IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease.Successful use of rituximab in a young patient with immunoglobulin G4-related disease and refractory scleritis.Resistant Behçet disease responsive to anakinra.High-density lipoproteins inhibit urate crystal-induced inflammation in mice.Erosive osteoarthritisBalneotherapy in chronic inflammatory rheumatic diseases-a narrative reviewDevelopment and Role in Therapy of Canakinumab in Adult-Onset Still's DiseaseSafety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational studyBlau syndrome and latent tubercular infection: an unresolved partnership
P50
Q21203670-ABB8ACB1-4F82-485E-9580-81C36CDDD7DDQ26777464-4A9E3ACD-0093-43C7-889C-31A9D9AF4DEFQ26778253-5242570A-AF41-44C2-887C-31233F507900Q28217596-AC2BF6EC-EAE6-4BEC-BD5D-DC8E0CDCA147Q33357128-61D0445D-9A66-40A7-9E2C-16E1931013F4Q33873710-078B6669-C145-4732-8765-F5F84C2C4C4BQ35559391-C6E5543D-8FFF-4A75-AD89-8DF3B5C14341Q35619403-37431D92-8CFE-4FA6-8F23-CE119E5AA9EFQ36940165-E76D83B0-31C5-46CB-AB55-ED3D166CD54DQ37249170-895F7D7A-2A31-4CC4-9D78-9BE42881AF66Q37361075-D62FBB04-304F-49AA-856B-EFC1E0F9AD60Q37551323-816F46AA-E2AF-4ED1-9298-8758015FBAA1Q37771574-FC9FA681-9DE0-4040-B6CC-532548AF075BQ37964848-F999B98A-8029-4148-BA20-9A3B72AE004CQ38033878-7F0CA71E-29CF-40B5-A781-DA03CF236307Q38176123-29BC589D-A3A2-4060-A3C5-DEF062118810Q38245566-DA156757-7049-4CC0-A79B-90E9EDCAA5E9Q38413572-AB5050FB-FF4B-47F0-BA3B-31633750247DQ38703626-6CD8FD49-12C7-4C06-B153-1311C6DE4564Q38908705-2B7C4C6C-9577-4ED5-B4F7-8AE03D191A42Q39748097-0A42B865-2590-429D-9AC4-4440EEB22005Q39861020-01C9D70C-2CE6-4EA8-960D-7AA5BEC42776Q39886087-210BB21C-B788-482F-A683-79316306F284Q41131357-6C776E6D-1DA5-4ADB-B414-983023CC3352Q41906826-DB46E364-6B7B-4206-8365-4BD7EF820B43Q42101952-F6700278-1DEB-49DA-8C56-4EBAAA9A0CECQ42420342-BD41837E-B5D8-4179-9D53-78423D709981Q43050415-AD477504-58DF-48D3-88B0-CC52041D3BD3Q43209497-00244AB3-01B6-4503-B186-B5AF6D966062Q44130233-6E1C7D2F-199B-44BD-9450-157215998CCDQ44434121-F1E54BE0-B62E-442C-B403-4F2BDD06E0FBQ44665278-06710247-1DE6-49E7-9D7D-9066567BC901Q44732015-32B3E4CA-D188-4095-8E85-639FBEBBDF77Q46423669-74D41425-369A-4649-BCCB-95753E509CC2Q53079167-B8A22E25-21E9-451A-B5FB-A8B5FDE23F48Q56288813-A5AC7E79-695C-47A0-A4AE-2EF5059DF2A1Q57056048-B764E88D-6D40-4152-B862-C0AD26F4EB65Q57300052-E73D7181-BC0F-459E-AD8D-47E3E1B256B2Q58325876-907B0ACB-30A8-4873-AE78-EB69472F0889Q58326086-B1F9D498-6FFD-466C-B77F-B51D8FD86442
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0001-6432-7174
@en
name
Paolo Sfriso
@ast
Paolo Sfriso
@en
Paolo Sfriso
@es
Paolo Sfriso
@nl
type
label
Paolo Sfriso
@ast
Paolo Sfriso
@en
Paolo Sfriso
@es
Paolo Sfriso
@nl
prefLabel
Paolo Sfriso
@ast
Paolo Sfriso
@en
Paolo Sfriso
@es
Paolo Sfriso
@nl
P106
P1153
6603686369
P31
P496
0000-0001-6432-7174